Neurosense Therapeutics Ltd (NRSN)

$0.75 -0.04 (-4.53%)
Market Cap 10.59M
Revenue (ttm) 0.00
Net Income (ttm) -10.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 165,900
Avg Vol 216,708
Day's Range N/A - N/A
Shares Out 13.67M
Stochastic %K 1%
Beta 1.63
Analysts Strong Sell
Price Target $8.38

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
mmtiddy
mmtiddy Mar. 20 at 9:18 PM
$NRSN Massive sell order at 4PM today on a Friday, did they hit the ATM? Earnings is soon, would be telling how much they actual rate this current stock price
1 · Reply
supernoob
supernoob Mar. 20 at 6:30 PM
$NRSN I hope this works out 🥲
2 · Reply
supernoob
supernoob Mar. 20 at 6:30 PM
$NRSN just bought 1k more
0 · Reply
lev57
lev57 Mar. 20 at 5:42 PM
$NRSN Mr. 100$ is back again to lower the goal with all his might. Let's not let him dismantle the goal value.
0 · Reply
Babilon1210
Babilon1210 Mar. 20 at 7:10 AM
$NRSN Mass General Brigham research is one of the largest and most influential hospital-based research programs in the world.
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 19 at 11:19 PM
$NRSN bad week a very bad week…
0 · Reply
funnymoney90210
funnymoney90210 Mar. 19 at 9:38 PM
$NRSN
0 · Reply
Heap_Of_Funk
Heap_Of_Funk Mar. 19 at 2:39 PM
$NRSN or lower. Might go negative 👀🤷‍♀️
0 · Reply
Heap_Of_Funk
Heap_Of_Funk Mar. 19 at 2:38 PM
$NRSN cant even sue he is in israel first off and secondly has no money
1 · Reply
mmtiddy
mmtiddy Mar. 19 at 10:17 AM
$NRSN Stock dead on arrival, Alon seriously needs to get the sack. Doesn’t know how to run a publicly traded company, his empty promises should be sued for, how do we go from signing a binding term sheet to this?
1 · Reply
Latest News on NRSN
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Mar 18, 2026, 8:00 AM EDT - 3 days ago

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

Mar 16, 2026, 11:33 AM EDT - 5 days ago

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

Mar 9, 2026, 11:07 AM EDT - 12 days ago

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

Feb 18, 2026, 9:05 AM EST - 4 weeks ago

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

Feb 9, 2026, 9:20 AM EST - 5 weeks ago

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Jan 21, 2026, 8:30 AM EST - 2 months ago

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Jan 8, 2026, 8:45 AM EST - 2 months ago

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Dec 22, 2025, 9:17 AM EST - 3 months ago

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

Dec 4, 2025, 7:30 AM EST - 3 months ago

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

Nov 24, 2025, 9:56 AM EST - 4 months ago

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

NeuroSense to Host Investor Webinar on December 8, 2025

Nov 3, 2025, 9:15 AM EST - 4 months ago

NeuroSense to Host Investor Webinar on December 8, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Oct 6, 2025, 9:00 AM EDT - 5 months ago

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 10, 2025, 2:30 PM EDT - 6 months ago

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Sep 4, 2025, 8:49 AM EDT - 7 months ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Provides Business Update and Progress for the First Half of 2025

Aug 1, 2025, 9:00 AM EDT - 8 months ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Jul 22, 2025, 8:42 AM EDT - 8 months ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025, 3:08 PM EDT - 11 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025, 8:45 AM EDT - 11 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 24, 2025, 9:09 AM EDT - 11 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 9, 2025, 8:30 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 7, 2025, 5:14 PM EDT - 1 year ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Apr 4, 2025, 9:10 AM EDT - 1 year ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Mar 17, 2025, 8:30 AM EDT - 1 year ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Jan 6, 2025, 9:00 AM EST - 1 year ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 23, 2024, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 18, 2024, 10:25 AM EST - 1 year ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 11, 2024, 9:25 AM EST - 1 year ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 4, 2024, 8:30 AM EST - 1 year ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Dec 2, 2024, 8:30 AM EST - 1 year ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Nov 21, 2024, 9:20 AM EST - 1 year ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 28, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 24, 2024, 8:30 AM EDT - 1 year ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 15, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 9, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Oct 7, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Sep 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 30, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 7, 2024, 2:00 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 14, 2024, 9:05 AM EDT - 2 years ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 7, 2024, 8:45 AM EDT - 2 years ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces First Quarter 2024 Business Update

May 2, 2024, 9:19 AM EDT - 2 years ago

NeuroSense Announces First Quarter 2024 Business Update

mmtiddy
mmtiddy Mar. 20 at 9:18 PM
$NRSN Massive sell order at 4PM today on a Friday, did they hit the ATM? Earnings is soon, would be telling how much they actual rate this current stock price
1 · Reply
supernoob
supernoob Mar. 20 at 6:30 PM
$NRSN I hope this works out 🥲
2 · Reply
supernoob
supernoob Mar. 20 at 6:30 PM
$NRSN just bought 1k more
0 · Reply
lev57
lev57 Mar. 20 at 5:42 PM
$NRSN Mr. 100$ is back again to lower the goal with all his might. Let's not let him dismantle the goal value.
0 · Reply
Babilon1210
Babilon1210 Mar. 20 at 7:10 AM
$NRSN Mass General Brigham research is one of the largest and most influential hospital-based research programs in the world.
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 19 at 11:19 PM
$NRSN bad week a very bad week…
0 · Reply
funnymoney90210
funnymoney90210 Mar. 19 at 9:38 PM
$NRSN
0 · Reply
Heap_Of_Funk
Heap_Of_Funk Mar. 19 at 2:39 PM
$NRSN or lower. Might go negative 👀🤷‍♀️
0 · Reply
Heap_Of_Funk
Heap_Of_Funk Mar. 19 at 2:38 PM
$NRSN cant even sue he is in israel first off and secondly has no money
1 · Reply
mmtiddy
mmtiddy Mar. 19 at 10:17 AM
$NRSN Stock dead on arrival, Alon seriously needs to get the sack. Doesn’t know how to run a publicly traded company, his empty promises should be sued for, how do we go from signing a binding term sheet to this?
1 · Reply
Speculator2
Speculator2 Mar. 18 at 9:58 PM
$NRSN https://www.sec.gov/edgar/browse/?CIK=0001875091 for all the filings
1 · Reply
Speculator2
Speculator2 Mar. 18 at 9:57 PM
$NRSN The 6 filings from today are all Form 3s on behalf of insiders. They are locked in, underwater, and waiting for the same catalysts as us.
0 · Reply
Speculator2
Speculator2 Mar. 18 at 9:54 PM
$NRSN the CMO is sitting on $3.51 options https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319882599&type=HTML&cdn=8b8cab4e1f612aa9c796b8f4802f1cbc&formType=3&dateFiled=2026-03-18&cik=1875091&symbol=1875091&companyName=
0 · Reply
lev57
lev57 Mar. 18 at 6:35 PM
$NRSN Mr. 100 is back again to lower the goal with all his might. Let's not let him dismantle the goal value.
0 · Reply
mmtiddy
mmtiddy Mar. 18 at 3:18 PM
$NRSN Have you never traded bio stocks, because it clearly shows. Most bio stocks lose value after a catalyst, the funny thing is that no one gave this stock a chance and it still fell down
0 · Reply
lev57
lev57 Mar. 18 at 2:54 PM
$NRSN https://neurosense.investorroom.com/2026-03-18-C-O-R-R-E-C-T-I-O-N-NeuroSense
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 18 at 2:49 PM
$NRSN i have never seen such a stock that fails time after time after ”good” news. at that rate if the company signs on partnership deal the value of the company will go to zero!
0 · Reply
funnymoney90210
funnymoney90210 Mar. 18 at 2:46 PM
$NRSN news correction
0 · Reply
Speculator2
Speculator2 Mar. 17 at 6:16 PM
$NRSN My hope is that yesterday publication of the trial results in JAMA Neurology will be a tailwind for that April meeting in Canada, as it provides peer-reviewed validation for the data they are about to present to the regulators.
0 · Reply
supernoob
supernoob Mar. 17 at 2:31 PM
$NRSN feels like partnership maybe in Q3, just gotta diamond hand.
1 · Reply
lev57
lev57 Mar. 17 at 2:17 PM
$NRSN PrimeC demonstrated comparable safety to placebo and showed slowed functional decline, reduced ALS-related complications, and modulation of iron-regulatory and microRNA biomarkers in adults with האשטג#ALS over 18 months of treatment.
0 · Reply
Stekli27
Stekli27 Mar. 17 at 2:05 PM
$NRSN NeuroSense Therapeutics Price Target Maintained With a $14.00/Share by D. Boral Capital - 03/17/2026 14:09
0 · Reply